NCT03599765
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations:
Breast Cancer Tissue:
Recruitment Status: Recruiting
Phase 2
Drug Category: Radiation Therapy, Other
Key Eligibility Criteria:
Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases:
Additional Notes:
Exclusions: Patients with more than 4 prior lines of systemic therapy administered to treat metastatic disease; Patients with diffuse metastatic processes including leptomeningeal disease; Patients with metastatic effusion (e.g. pleural effusion or ascites)
https://ClinicalTrials.gov/show/NCT03599765